Philip A. Carpino

Xenon Pharmaceuticals (Canada) — Canada

Neuroscience · Life Sciences

26h-index2.0kcitations70works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Regulation of Appetite and Obesity(12), Chemical Synthesis and Analysis(12), Cannabis and Cannabinoid Research(8), Carbohydrate Chemistry and Synthesis(8), Receptor Mechanisms and Signaling(8)

Publications70 total

Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M<sup>pro</sup> from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants
Journal of Medicinal Chemistry·2024· 4 cited
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs
Expert Opinion on Therapeutic Patents·2024· 3 cited
Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The American Journal of Cardiology·2021· 28 cited
Nonpeptide Antagonists at Peptide Receptors
2020
Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors
ACS Medicinal Chemistry Letters·2018· 7 citedOpen Access
Diabetes area patent participation analysis – part II: years 2011-2016
Expert Opinion on Therapeutic Patents·2017· 14 cited
Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience
Annals of Cardiothoracic Surgery·2017· 116 citedOpen Access
Practical synthesis of capromorelin, a growth hormone secretagogue, via a crystallization-induced dynamic resolution
Bioorganic & Medicinal Chemistry·2016· 6 cited
Positive Allosteric Modulators of G-Protein-Coupled Receptors that Act <i>via</i> Covalent Mechanisms of Action
2016
A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation
Cell chemical biology·2016· 95 citedOpen Access
Development of a selective activity-based probe for glycosylated LIPA
Bioorganic & Medicinal Chemistry Letters·2016· 3 cited
CCDC 1517678: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2<i>H</i>)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases
Journal of Medicinal Chemistry·2015· 57 citedOpen Access
MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1
ACS Chemical Biology·2015· 15 cited
Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
Journal of Medicinal Chemistry·2015· 80 cited
Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3
Journal of Medicinal Chemistry·2015· 15 citedOpen Access
Latest approaches for the treatment of obesity
Expert Opinion on Drug Discovery·2015· 126 cited
Melanocortin-4 Receptor Modulators for the Treatment of Obesity: a Patent Analysis (2008–2014)
Pharmaceutical Patent Analyst·2015· 9 cited
Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms
Structure·2014· 179 citedOpen Access
Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies
Expert Opinion on Investigational Drugs·2014· 23 cited
page 1 of 4Next →

Frequent Co-authors

John R. Hadcock(9), David Hepworth(8), Markus Boehm(7), David A. Griffith(7), Robert L. Dow(7), Dennis O. Scott(7), Philip A. Iredale(6), Paul DaSilva‐Jardine(6), Colin R. Rose(6), Roger B. Ruggeri(5), Kay Ahn(5), Shawn C. Black(5), Rebecca E. O’Connor(5), Shawn Cabral(4), Aaron Smith(4), Andreas Spaltenstein(4), Paul B. Hopkins(4), Joseph DiBrino(4), Bruce A. Lefker(4), Denise Gautreau(4)